Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
BioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.
The global biopharmaceutical company said that it is well capitalized with cash, cash equivalents, restricted cash, and investments of as much as $222.8 million as of 30 June 2021.
The companies will harness the power of machine learning to increase the scalability of medicines based on spirulina, a type of blue-green algae.
Moderna will construct a manufacturing facility in Canada to provide direct access to mRNA vaccines for the COVID-19 pandemic and future viral threats and respiratory viruses.
Check out where the money went in the life sciences industry this week.
Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.
On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.
The Cambridge, Mass.-based company announced that industry veteran Grant Bogle has taken over as president and CEO.
As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.
Months after landing a massive SPAC deal that carried Ginkgo Bioworks to the Nasdaq, the company is now touting a manufacturing breakthrough from partner Aldevron for mRNA vaccine components.